Le Lézard
Classified in: Health
Subject: PDT

Enzymedica Unveils Fasting Today: First-of-Its-Kind Product Revolutionizes Intermittent Fasting with Innovative Formula


VENICE, Fla., May 2, 2024 /PRNewswire/ -- Enzymedica®, a leading manufacturer and pioneer of dietary supplements, has launched its latest innovation, Fasting Today®. The brand's new, groundbreaking formula is crafted to meet the nutritional needs of intermittent fasters in one convenient drink mix thanks to a trio of essential ingredients including electrolytes, fiber and amino acids.

Intermittent fasting has become an increasingly popular health practice with growing consumer interest in recent years. While there are alternate ways to implement the process, many involve alternating cycles of fasting and then eating within a set number of hours. Scientific research concludes that intermittent fasting supports weight management, increased energy levels, brain health and healthy aging.

Enzymedica formulated Fasting Today to support those embracing the practice of time-restricted dieting with added nutrients essential during fasting periods. Fasting Today won't break a fast. It is crafted with sustainably-sourced baobab fiber to reduce hunger, essential amino acids to support muscle strength and body composition and a balanced mix of key electrolytes to maintain optimal hydration and support critical bodily functions, including cardiovascular and brain health.*

"At Enzymedica, we're always at the forefront of innovation, listening to the needs of our consumers and crafting solutions that truly make a difference in their lives," said Ryan Sensenbrenner, senior director of marketing at Enzymedica. "We understand the growing interest in intermittent fasting and the importance of feeling your best during fasting periods. With Fasting Today, we aim to provide a comprehensive product that enhances this experience and empowers individuals to achieve their health goals with confidence."

Fasting Today is vegan and keto-friendly as well as soy-free, dairy-free and gluten-free, and it contains no artificial flavors or colors. It has a tropical pineapple flavor and comes in a tall 9.31-ounce container with 24 servings. Consumers can stir one scoop into 12 ounces of water and enjoy, once or twice daily. It can also be purchased at local health food, specialty grocery stores and various online retailers.

To learn more about or purchase Enzymedica products, visit https://enzymedica.com/.

About Enzymedica
Since 1998, Enzymedica has helped make great health easier for everyone. A leader in natural digestive health and wellness, they formulate clean, effective products made without compromise using high-quality, scientifically validated ingredients. In addition to Digest Gold®, America's #1 selling digestive enzyme formula, Enzymedica's extensive range includes innovative supplements for digestive health, occasional heartburn, metabolic balance, immune health and more.* The independently owned company is based in Venice, Florida.

*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease.

Media Contact
Anjie Oberholzer
(484) 241-6926
[email protected] 

SOURCE Enzymedica


These press releases may also interest you

at 02:00
QuTEM AB (formerly Vironova BioAnalytics AB), a leading provider of transmission electron microscopy (TEM) services, proudly announces the receipt of GMP (Good Manufacturing Practice) Certificates and Manufacturing Permits for Independent Quality...

at 01:54
FIRST QUARTER (JANUARY - MARCH 2024) Oder intake SEK 238.5 M (206.6)Net sales SEK 257.2 M (230.2)Operating profit SEK 45.8 M (23.7)Profit after tax SEK 36.7 M (17.6)Earnings per share before/after dilution SEK 1.07 (0.51)Cash flow SEK 87.9 M...

at 01:00
In response to valuable feedback from our customers, Luraco Technologies is thrilled to announce the launch of an upgrade to our medical massage chair lineup. We are introducing the Luraco i9 Max Plus Series, a revolution of the i9 Max Series. The i9...

at 00:01
Celltrion USA today announced it will present the two-year results from the extended LIBERTY studies (LIBERTY-CD and LIBERTY-UC) in adult patients...

16 mai 2024
Proteologix, Inc., a privately-held biotechnology company focused on bispecific antibodies for immune-mediated diseases, today announced that it has entered into a definitive agreement to be acquired by Johnson & Johnson for $850 million in cash,...

16 mai 2024
Seelos Therapeutics, Inc. ("Seelos" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system ("CNS") disorders and rare diseases, announced today that it has entered into a...



News published on and distributed by: